MacroGenics faces a class-action lawsuit over alleged misleading statements about Phase 2 TAMARACK study data of MGC018 for mCRPC.

MacroGenics, Inc. (MGNX) faces a class-action lawsuit over alleged misleading statements regarding Phase 2 TAMARACK study data of antibody-drug conjugate MGC018 (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). The lawsuit claims the company misled investors about interim safety data, causing a share price surge followed by a decline after disclosing five patient deaths. Hagens Berman is leading the lawsuit, and investors may join as plaintiffs until September 24, 2024.